Targeting Androgen Receptor in Breast Cancer: Enzalutamide as a Novel Breast Cancer Therapeutic
Technical Report,15 Aug 2015,14 Aug 2016
University of Colorado Denver Aurora United States
Pagination or Media Count:
Enzalutamide has clinical activity in breast cancer as a single agent and in combination with exemestane. Activity is seen in both triple negative AR BC and also ER AR BC. Clinical data in Her2 AR BC is too immature to make conclusions. The proposed clinical trials for Years 3-5 appear to be justified based on clinical activity and the current preclinical data.
- Medicine and Medical Research